Search Results

DiaCarta, Inc. (“DiaCarta”), a pioneer in developing innovative molecular technologies to transform patient care by providing effective precision diagnostics using liquid biopsy in cancer and infectious diseases has established a strategic collaboration with Capstone Health Alliance, one of the largest regional group purchasing organizations (GPO) in the US healthcare sector.

DiaCarta, Inc. today announced that it has established a strategic collaboration with OncoAssure Ltd, an Irish medical diagnostics company.

DiaCarta proudly announced that the Oncuria® Bladder Cancer Tests, developed by Nonagen Bioscience and validated by DiaCarta as a Lab Developed Test (LDT), at its CAP-accredited and CLIA-certified laboratory, have received Medicare coverage effective January 1, 2024.

DiaCarta, a leading molecular diagnostics company specializing in personalized patient care through liquid biopsy, proudly announced that Florida Health Department selected “using plasma DNA concentration (DiaCarta’s RadTox™ test) for early detection of treatment response and resistance” through the Casey DeSantis Florida Cancer Innovation Fund.

DiaCarta, a leading molecular diagnostics company personalizing patient care through liquid biopsy, proudly announced that its revolutionary RadTox™ test, designed for tumor response monitoring, is now eligible for reimbursement from Medicare, effective January 1, 2024.

DiaCarta, Inc. announced that DiaCarta received US FDA 510 clearance for it’s over the counter at home iColon Fecal Occult Blood Test that enables early detection of blood in stool at home, which is clinically relevant in gastrointestinal disorders and colorectal cancer.

AnchorDx announced that it has entered into a long-term collaboration with DiaCarta, a precision molecular diagnostics company and developer of novel oncology and infectious disease tests, for product development and global commercialization in the cancer screening arena.

DiaCarta, Ltd. today announced the termination of its Business Combination Agreement with HH&L Acquisition Co.

DiaCarta, Ltd., a novel molecular diagnostic test developer for cancer and infectious diseases, announced that it has received accreditation by the College of American Pathologists for its CLIA certified lab.

DiaCarta, Ltd. today announced that the company has formed strategic partnership with New Jersey-based Hopkins MedTech Compliance (HMC) and Hopkins MedTech Lab Services (HML) to support the unmet needs for regulatory compliance and laboratory developed test (LDT) validation of in vitro diagnostics (IVD) in the United States.